Compare BNL & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNL | BLLN |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.5B |
| IPO Year | 2008 | N/A |
| Metric | BNL | BLLN |
|---|---|---|
| Price | $19.74 | $78.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | $20.22 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 3.3M | 281.7K |
| Earning Date | 04-29-2026 | 03-04-2026 |
| Dividend Yield | ★ 5.93% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $454,138,000.00 | N/A |
| Revenue This Year | $7.99 | $45.96 |
| Revenue Next Year | $5.27 | $30.11 |
| P/E Ratio | $39.41 | ★ N/A |
| Revenue Growth | ★ 5.17 | N/A |
| 52 Week Low | $15.15 | $61.96 |
| 52 Week High | $19.91 | $138.70 |
| Indicator | BNL | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 63.64 | 50.17 |
| Support Level | $17.98 | $64.99 |
| Resistance Level | $19.82 | $83.20 |
| Average True Range (ATR) | 0.39 | 6.77 |
| MACD | 0.12 | 1.24 |
| Stochastic Oscillator | 93.14 | 43.51 |
Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.